| 格式化内容附注： | Overview of Anti-CTLA-4 agents : ipilimumab and tremilimumab / Daniel Hartman Johnson and Jianjun Gao -- Overview of PD-1 and PD-l1 inhibitors / Nikolaos Andreatos, Shailender Bhatia, and Petros Grivas -- Indications and toxicities of immune checkpoint inhibitor combinations / Lavinia Spain, Michael A. Postow, James Larkin, and Jeffrey Weber -- General principles of immune-related toxicities / Osama E. Rahma and Patrick A. Ott -- Dermatological toxicities : rash, mucosal irritation, and pruritus / Jennifer Wu and Mario E. Lacouture -- Musculoskeletal and rheumatologic toxicities / Noha Abdel-Wahab, Clifton O. Bingham III, and Maria Suarez-Almazor -- Immune-related gastrointestinal toxicities / Hamzah Abu-Sbeih, Daniel Johnson, Yinghong Wang -- Pneumotoxicity associated with immune checkpoint blockades / Vickie R. Shannon -- Immune-related endocrinopathies associated with immune checkpoint inhibitors / Rajeev Sharma, Ha Nguyen, Ramona Dadu -- Neurologic adverse events and neurologic complications / Haroon Ahmad, Jasmin Jo, Elizabeth Gaughan, Camilo Fadul -- Cardiovascular toxicities related to immune checkpoint inhibitors / Pankit Vachhani, Igor Puzanov, Javid J. Moslehi -- Renal toxicities associated with immune checkpoint inhibitors / Ala Abudayyeh, Maen Abdelrahim, Laurence Albiges -- Hematologic toxicities of apparent immune-related origins / George L. Chen, Caroline Robert, Alexander M. Lesokhin -- Ocular toxicities caused by immune dysregulation / Liliya Golas and Dimitra Skondra -- Safety and regulation of immune checkpoint inhibitors in special patient populations / Douglas B. Johnson, Ryan Sullivan, Paolo A. Ascierto -- Cancer-related fatigue in patients of immune checkpoint inhibitor therapy / Eric D. Hansen, Michelle Walter, Amy A. Case -- Cost effectiveness and financial toxicity in new cancer therapies / Christine Kohn, Natalia Shcherbakova, Alberto J. Montero. |
|---|